Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Microvesículas endoteliales con efecto microbicida para la preparación de un medicamento o uso directo

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20181015004
Publicado:
02/11/2018
Caducidad:
03/11/2019
Resumen:
Un grupo de investigación de una universidad española ha desarrollado microvesículas endoteliales con efecto microbicida. Estas vesículas destruyen los principales patógenos implicados en la sepsis e incluso cepas derivadas de ellos resistentes a múltiples antibióticos. La invención se refiere, como primer aspecto, al uso de microvesículas endoteliales (MVe) para hacer un nuevo medicamento (preferiblemente un antibiótico), ya que tienen una potente capacidad antimicrobiana tanto sobre los principales patógenos implicados en la sepsis como en bacterias multirresistentes a los antibióticos convencionales. Estas MVs causan la destrucción de bacterias pero no afectan a las células eucariotas. Alternativamente, esta invención también se refiere a MV derivadas de células endoteliales para su uso como medicamento. El grupo de investigación busca compañías farmacéuticas e institutos de I+D interesados en diseñar nuevos medicamentos para establecer acuerdos de licencia, cooperación o comercialización con asistencia técnica.

Details

Tittle:
Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct use.
Summary:
A research group from a Spanish university has developed endothelial microvesicles with microbicidal effect. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R-Y-D institutions interested in the design of new medicines.
Description:
Sepsis is one of the leading causes of mortality worldwide. 20 to 30 million cases of sepsis are registered annually in the world, with 50 people being killed every hour.
Annually, it affects 50,000 people in Spain, of whom 17,000 die. In the last ten years, cases of sepsis have doubled and studies believe that the trend will continue to be high.
Recent studies on sepsis and infection in vivo have seen a great increase of microvesicles (MV) in blood and have studied the utility of said MV for the differentiation between other pathologies of bacterial origin. MVs play an important role in the defense against pathogens that are therefore beneficial as part of the natural response to infection.
The present invention, therefore, refers, as a first aspect, to the use of endothelial microvesicles (MVe) to make a new medicament (preferably an antibiotic), since they possess a potent antimicrobial capacity both on the main pathogens involved in sepsis as well as on multiresistant bacterias to the conventional antibiotics. These MVs cause the destruction of bacteria but do not affect eukaryotic cells. Alternatively, the present invention also relates to MV derived from endothelial cells for its use as a medicament.
This new function discovered about the MV is of great diagnostic utility and also offers a wide variety of therapeutic targets, as well as an alternative to antibiotics for the treatment of infectious pathologies such as sepsis. That bactericidal action of the MVe of the invention is carried out even at physiological concentrations, and with a high concentration of microorganisms, specifically bacteria, being this action stronger when higher is the concentration of MVe.
The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R-Y-D institutions interested in the design of new medicines.
Advantages and Innovations:
- Use of endothelial microvesicles as an alternative to antibiotics.
- The treatment with the MVe of the invention does not induce physiopathological changes in eukaryotic cells.
- The antimicrobial activity associated with the MVe of the invention is not dependent on the complement line and is very stable.
- The MVe have bactericidal activity both against Gram-type bacteria and against Gram + bacteria.
- The pharmaceutical composition of the present invention accepts to contain additives to increase, control or otherwise direct the desired therapeutic effect of the MVe of the invention (buffering agents, surfactants, cosolvents, preservatives, etc ...)
- The pharmaceutical composition can be administered by conventional means: intravenously, trocars, cannulae. And, in addition, it allows direct administration by injection, on the external surface of the affected organ or tissue.
- The pharmaceutical composition can be stored up to the moment of its application by conventional methods known to those skilled in the art.
- It is resistant to freezing and thermal treatments up to 85ºC.
- They have also been shown to be effective against the biofilms that form these microorganisms.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The patent has been applied in Spain.

Partner sought

Type and Role of Partner Sought:
The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R-Y-D institutions interested in the design of new medicines.

Companies of the target sectors previously mentioned are sought to exploit the results of the invention via licensing and/or commercial agreements with technical cooperation.

Research institutions or companies with a solid R-Y-D background are sought for cooperation agreements in order to foster the technology already developed to a next stage.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06002008 Microbiología